AR108317A1 - Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 - Google Patents
Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4Info
- Publication number
- AR108317A1 AR108317A1 ARP170101046A ARP170101046A AR108317A1 AR 108317 A1 AR108317 A1 AR 108317A1 AR P170101046 A ARP170101046 A AR P170101046A AR P170101046 A ARP170101046 A AR P170101046A AR 108317 A1 AR108317 A1 AR 108317A1
- Authority
- AR
- Argentina
- Prior art keywords
- approximately
- antibody
- antigen
- ctla
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940045513 CTLA4 antagonist Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 229950009791 durvalumab Drugs 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 229950007217 tremelimumab Drugs 0.000 abstract 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan aquí composiciones que comprenden la coformulación de anticuerpos anti-PD-L1 y anti-CTLA-4, o fragmentos de unión a antígeno de los mismos, y métodos para fabricar y usar tales composiciones. En diversos aspectos, se proporcionan coformulaciones estables del anticuerpo anti-PD-L1 durvalumab (MEDI4736) y el anticuerpo anti-CTLA-4 tremelimumab. Reivindicación 1: Una composición que comprende durvalumab, o un fragmento de unión a antígeno del mismo, y tremelimumab, o un fragmento de unión a antígeno del mismo, en el que la concentración de durvalumab, o un fragmento de unión a antígeno del mismo, es de aproximadamente 18,7 mg/mL a aproximadamente 44,4 mg/mL y en el que la concentración de tremelimumab, o un fragmento de unión a antígeno del mismo, es de aproximadamente 2,2 mg/mL a aproximadamente 12,5 mg/mL. Reivindicación 17: Una composición farmacéutica que comprende o que consiste de aproximadamente 44,4 mg/mL de durvalumab, o un fragmento de anticuerpo del mismo, aproximadamente 2,2 mg/mL de tremelimumab, o un fragmento de anticuerpo del mismo, aproximadamente 25 mM de Histidina / Histidina-HCl, aproximadamente 269 mM de deshidrato de trehalosa aproximadamente 0,03 mM de EDTA y aproximadamente 0,02% p/v de PS80 a un pH de aproximadamente 6,0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662327214P | 2016-04-25 | 2016-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108317A1 true AR108317A1 (es) | 2018-08-08 |
Family
ID=60089975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101046A AR108317A1 (es) | 2016-04-25 | 2017-04-25 | Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10421811B2 (es) |
| EP (1) | EP3448428A4 (es) |
| JP (1) | JP2019514889A (es) |
| KR (1) | KR20180135475A (es) |
| CN (1) | CN109069631A (es) |
| AR (1) | AR108317A1 (es) |
| AU (1) | AU2017257505B2 (es) |
| BR (1) | BR112018071287A2 (es) |
| CA (1) | CA3020893A1 (es) |
| CL (1) | CL2018002998A1 (es) |
| CO (1) | CO2018011195A2 (es) |
| IL (1) | IL262344A (es) |
| MA (1) | MA44783A (es) |
| MX (1) | MX2018012651A (es) |
| RU (1) | RU2018140960A (es) |
| SG (1) | SG11201807474SA (es) |
| TW (1) | TW201740976A (es) |
| WO (1) | WO2017189433A1 (es) |
| ZA (1) | ZA201807888B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101888321B1 (ko) * | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| BR112016005303A2 (pt) | 2013-09-11 | 2017-09-12 | Medimmune Ltd | anticorpos anti-b7-h1 para tratamento de tumores |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| RS59134B1 (sr) * | 2014-05-13 | 2019-09-30 | Medimmune Ltd | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| SG11201811003PA (en) | 2016-06-13 | 2019-01-30 | I Mab | Anti-pd-l1 antibodies and uses thereof |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
| US20200354453A1 (en) * | 2017-05-02 | 2020-11-12 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| MX2019014265A (es) | 2017-06-01 | 2020-08-03 | Compugen Ltd | Tratamientos conjuntos triples con anticuerpos. |
| WO2019206987A1 (en) * | 2018-04-25 | 2019-10-31 | Medimmune Limited | Formulations of human anti-pd-l1 antibodies |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| AU2021415180A1 (en) * | 2020-12-30 | 2023-07-06 | I-Mab Biopharma Us Limited | Formulations of anti-cd73 antibodies |
| EP4611898A1 (en) * | 2022-11-04 | 2025-09-10 | Astrazeneca AB | Anti-ctla antibody compositions and related methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006096490A2 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US8217149B2 (en) * | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| LT3279215T (lt) * | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| EP2538973A2 (en) * | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Stable antibody containing compositions |
| CA3111357A1 (en) * | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| RS59134B1 (sr) * | 2014-05-13 | 2019-09-30 | Medimmune Ltd | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća |
| WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| AU2015335029B2 (en) * | 2014-10-24 | 2021-09-23 | Astrazeneca Ab | Combination |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
-
2017
- 2017-04-24 AU AU2017257505A patent/AU2017257505B2/en not_active Ceased
- 2017-04-24 WO PCT/US2017/029143 patent/WO2017189433A1/en not_active Ceased
- 2017-04-24 JP JP2018555566A patent/JP2019514889A/ja active Pending
- 2017-04-24 KR KR1020187033315A patent/KR20180135475A/ko not_active Ceased
- 2017-04-24 US US15/495,388 patent/US10421811B2/en not_active Expired - Fee Related
- 2017-04-24 MA MA044783A patent/MA44783A/fr unknown
- 2017-04-24 EP EP17790189.9A patent/EP3448428A4/en not_active Withdrawn
- 2017-04-24 CA CA3020893A patent/CA3020893A1/en not_active Abandoned
- 2017-04-24 MX MX2018012651A patent/MX2018012651A/es unknown
- 2017-04-24 CN CN201780023036.3A patent/CN109069631A/zh active Pending
- 2017-04-24 BR BR112018071287-6A patent/BR112018071287A2/pt not_active IP Right Cessation
- 2017-04-24 SG SG11201807474SA patent/SG11201807474SA/en unknown
- 2017-04-24 RU RU2018140960A patent/RU2018140960A/ru not_active Application Discontinuation
- 2017-04-25 TW TW106113795A patent/TW201740976A/zh unknown
- 2017-04-25 AR ARP170101046A patent/AR108317A1/es unknown
-
2018
- 2018-10-14 IL IL262344A patent/IL262344A/en unknown
- 2018-10-19 CO CONC2018/0011195A patent/CO2018011195A2/es unknown
- 2018-10-22 CL CL2018002998A patent/CL2018002998A1/es unknown
- 2018-11-22 ZA ZA2018/07888A patent/ZA201807888B/en unknown
-
2019
- 2019-08-28 US US16/553,670 patent/US20190382494A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018002998A1 (es) | 2018-12-07 |
| RU2018140960A (ru) | 2020-05-26 |
| AU2017257505B2 (en) | 2020-05-14 |
| MX2018012651A (es) | 2019-01-30 |
| IL262344A (en) | 2018-11-29 |
| CO2018011195A2 (es) | 2018-10-31 |
| US20190382494A1 (en) | 2019-12-19 |
| JP2019514889A (ja) | 2019-06-06 |
| CA3020893A1 (en) | 2017-11-02 |
| SG11201807474SA (en) | 2018-11-29 |
| ZA201807888B (en) | 2019-08-28 |
| KR20180135475A (ko) | 2018-12-20 |
| US10421811B2 (en) | 2019-09-24 |
| AU2017257505A1 (en) | 2018-12-06 |
| CN109069631A (zh) | 2018-12-21 |
| BR112018071287A2 (pt) | 2019-02-19 |
| TW201740976A (zh) | 2017-12-01 |
| EP3448428A4 (en) | 2019-11-27 |
| US20170306025A1 (en) | 2017-10-26 |
| RU2018140960A3 (es) | 2020-08-03 |
| EP3448428A1 (en) | 2019-03-06 |
| MA44783A (fr) | 2019-03-06 |
| WO2017189433A1 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108317A1 (es) | Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| AR133453A2 (es) | Composición farmacéutica de anticuerpos anti-cgrp | |
| EA201891694A1 (ru) | Фармацевтическая композиция, содержащая конструкты биспецифических антител | |
| CL2019000681A1 (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| EA202190986A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit | |
| MX381232B (es) | Formulación de anticuerpos. | |
| EA202190808A2 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA201792451A1 (ru) | Антитела к ox40 и способы их применения | |
| SG11201807765PA (en) | Antibody-containing preparation | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
| EA201791733A1 (ru) | Производные 9h-пирролодипиридина | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |